Lacosamide

Overview

Lacosamide is an antiepileptic drug used primarily to treat partial-onset seizures. It works by selectively enhancing slow inactivation of voltage-gated sodium channels, thereby stabilizing hyperexcitable neuronal membranes.

API suppliers (31)

Suppliers of Lacosamide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• BEIJING HOPE PHARMACEUTICAL CO LTD2 active DMF
• INDOCO REMEDIES LTDIndia2 active DMF GMP on record
• MSN PHARMACHEM PRIVATE LTDIndia2 active DMF
• CURIA MISSOURI INC1 active DMF
• Hetero Drugs LimitedIndia1 active DMF GMP on record
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• SIGNA SA DE CV1 active DMF
• Intas Pharmaceuticals Ltd.India1 active DMF GMP on record
• SYMPHONY PHARMA LIFESCIENCES PRIVATE LTDIndia1 active DMF
• JUBILANT BIOSYS LTDIndia1 active DMF
• LEE PHARMA LTDIndia1 active DMF GMP on record
• ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
• Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
• Divis LaboratoriesIndia1 active DMF GMP on record
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• CAMBREX PROFARMACO MILANO SRLItaly1 active DMF GMP on record
• HIKAL LTDPakistan1 active DMF
• Unichem Laboratories Ltd.India1 active DMF GMP on record
• CHIERON ACTIVE INGREDIENTS PRIVATE LTDIndia1 active DMF
• GLAND PHARMA LTDIndia1 active DMF GMP on record
• EMNAR PHARMA PRIVATE LTDIndia1 active DMF
• METROCHEM API PRIVATE LTDIndia1 active DMF
• Viyash Scientific LtdIndia1 active DMF GMP on record
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• CHROMO LABORATORIES INDIA PRIVATE LTDIndia1 active DMF

Showing 25 of 31 suppliers — see the full list in the app.

EU CEP holders (20)

Companies holding a valid EU Certificate of Suitability (CEP) for Lacosamide, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (81 approved US products), the latest listed US patent on Lacosamide expires 5 Jun 2040 and exclusivity 28 Apr 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas